LivaNova (NASDAQ:LIVN) Price Target Lowered to $64.00 at Needham & Company LLC

LivaNova (NASDAQ:LIVN) had its price objective lowered by Needham & Company LLC from $75.00 to $64.00 in a research note released on Wednesday morning,Benzinga reports. The firm currently has a buy rating on the stock.

Other equities analysts have also recently issued reports about the company. StockNews.com upgraded LivaNova from a “buy” rating to a “strong-buy” rating in a report on Friday, February 14th. Robert W. Baird raised their target price on LivaNova from $66.00 to $72.00 and gave the company an “outperform” rating in a report on Thursday, October 31st. Wolfe Research cut LivaNova from an “outperform” rating to a “peer perform” rating in a report on Wednesday. Finally, Mizuho lowered their target price on LivaNova from $80.00 to $70.00 and set an “outperform” rating for the company in a report on Thursday, October 31st. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $64.20.

LivaNova Stock Performance

NASDAQ LIVN opened at $41.45 on Wednesday. The stock has a fifty day simple moving average of $47.65 and a 200-day simple moving average of $49.56. LivaNova has a twelve month low of $40.37 and a twelve month high of $64.47. The stock has a market cap of $2.25 billion, a PE ratio of 98.69 and a beta of 1.00. The company has a current ratio of 3.37, a quick ratio of 2.87 and a debt-to-equity ratio of 0.46.

Insider Buying and Selling at LivaNova

In other news, Director Francesco Bianchi sold 1,250 shares of the firm’s stock in a transaction dated Wednesday, December 11th. The stock was sold at an average price of $50.99, for a total transaction of $63,737.50. Following the sale, the director now owns 7,522 shares of the company’s stock, valued at approximately $383,546.78. This trade represents a 14.25 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.27% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On LivaNova

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Russell Investments Group Ltd. raised its position in shares of LivaNova by 17.1% during the 4th quarter. Russell Investments Group Ltd. now owns 1,502 shares of the company’s stock worth $70,000 after acquiring an additional 219 shares in the last quarter. Summit Investment Advisors Inc. raised its position in shares of LivaNova by 1.7% during the 4th quarter. Summit Investment Advisors Inc. now owns 16,846 shares of the company’s stock worth $780,000 after acquiring an additional 289 shares in the last quarter. Atria Investments Inc raised its position in shares of LivaNova by 6.2% during the 3rd quarter. Atria Investments Inc now owns 5,653 shares of the company’s stock worth $297,000 after acquiring an additional 331 shares in the last quarter. State of Alaska Department of Revenue raised its position in shares of LivaNova by 7.3% during the 3rd quarter. State of Alaska Department of Revenue now owns 6,246 shares of the company’s stock worth $328,000 after acquiring an additional 425 shares in the last quarter. Finally, Xponance Inc. raised its position in shares of LivaNova by 6.1% during the 4th quarter. Xponance Inc. now owns 7,762 shares of the company’s stock worth $359,000 after acquiring an additional 445 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.